— Our Mission —
— Our Mission —
"No patient with peripheral T-cell lymphoma is left behind."
"No patient with peripheral T-cell lymphoma is left behind."
— Dr. Salvia Jain, Founder of PETAL Consortium —
— Dr. Salvia Jain, Founder of PETAL Consortium —
What is Peripheral T-cell Lymphoma?
Peripheral T-cell lymphoma (PTCL) is a rare and aggressive blood cancer, with about 7,000 new cases diagnosed in the US annually. Lymphoma is cancer of the lymphocytes, a type of white blood cell within the immune system. Peripheral T cells are a type of lymphocyte that destroy tumor cells and are found in the body's blood, lymph nodes, spleen, and other organs. Basically, PTCL is cancer of the cancer-fighting cells in the body.
What is PETAL Consortium?
What is PETAL Consortium?
In 2023, Salvia Jain, MD, a hematologist-oncologist at Massachusetts General Hospital, recognized the lack of systematic, multimodal longitudinal data for patients with PTCL. In response, she founded PETAL Consortium—a first-of-its-kind global network dedicated to advancing care for this rare and aggressive blood cancer by serving as a central hub of information.
PTCL’s rarity has significantly impeded research efforts and clinical trial development in a reasonable timeframe. PETAL overcomes this challenge by uniting leading centers of excellence in PTCL clinical care and research worldwide, enabling investigators to generate, collate, and access data from hundreds of patients.
Today, PETAL brings together more than 100 investigators from over 20 international research sites–spanning lymphoma medicine, artificial intelligence, systems biology, pathology, genomics, biostatistics, and bioinformatics–to accelerate discovery and transform how PTCL is understood and treated.
In 2023, Salvia Jain, MD, a hematologist-oncologist at Massachusetts General Hospital, recognized the lack of systematic, multimodal longitudinal data for patients with peripheral T-cell lymphoma (PTCL). In response, she founded PETAL Consortium—a first-of-its-kind global network dedicated to advancing care for this rare and aggressive blood cancer by serving as a central hub of information.
PTCL’s rarity has significantly impeded research efforts and clinical trial development in a reasonable timeframe. PETAL overcomes this challenge by uniting leading centers of excellence in PTCL clinical care and research worldwide, enabling investigators to generate, collate, and access data from hundreds of patients.
Today, PETAL brings together more than 100 investigators from over 20 international research sites–spanning lymphoma medicine, artificial intelligence, systems biology, pathology, genomics, biostatistics, and bioinformatics–to accelerate discovery and transform how PTCL is understood and treated.
Patients represented in PETAL research datasets
Clinicians and investigators working across institutions
Leading cancer centers participating in PETAL Consortium
Leading cancer centers participating in PETAL Consortium
Rare T-cell lymphoma subtypes studied across global cohorts
Multidisciplinary specialties including oncology, pathology, genomics, and AI
Peer-reviewed research publications in high-impact factor journals within 2 years generated through PETAL collaborations
Research
Research
Our mission is to create a centralized hub that integrates clinical, pathologic, treatment, radiologic, and molecular data into a comprehensive, multimodal dataset–enabling more precise, personalized treatment recommendations for patients.
Our mission is to create a centralized hub that integrates clinical, pathologic, treatment, radiologic, and molecular data into a comprehensive, multimodal dataset–enabling more precise, personalized treatment recommendations for patients.
Discovery & Innovation
Discovery & Innovation
We use cutting edge artificial intelligence and next generation sequencing technologies to identify new targets for drug development in collaboration with biotechnology and pharmaceutical partners.
We use cutting edge artificial intelligence and next generation sequencing technologies to identify new targets for drug development in collaboration with biotechnology and pharmaceutical partners.
Clinical Trials
Clinical Trials
PTCL’s heterogeneity, complexity and rarity has hindered development of clinical trials and accrual. PETAL addresses this barrier by providing a global clinical trial framework, adapting novel trial designs and modernizing protocols.
PTCL’s heterogeneity, complexity and rarity has hindered development of clinical trials and accrual. PETAL addresses this barrier by providing a global clinical trial framework, adapting novel trial designs and modernizing protocols.
Patient Care & Support
Patient Care & Support
HOPE-PTCL (Hub for Outreach and Patient Engagement in Peripheral T-cell Lymphoma) is PETAL’s patient education website, dedicated to empowering and connecting individuals and families affected by PTCL through knowledge, compassion, and community.
HOPE-PTCL (Hub for Outreach and Patient Engagement in Peripheral T-cell Lymphoma) is PETAL’s patient education website, dedicated to empowering and connecting individuals and families affected by PTCL through knowledge, compassion, and community.
Newsroom
Newsroom
February 2026
In this Q&A, meet Dr. Mwanasha Merrill, PETAL Consortium’s Principal Investigator at University of California, San Francisco!
Mwanasha Merrill, MD is a Clinical Assistant Professor and hematologist-oncologist at the University of California
February 2026
In this Q&A, meet Dr. Mwanasha Merrill, PETAL Consortium’s Principal Investigator at University of California, San Francisco!
Mwanasha Merrill, MD is a Clinical Assistant Professor and hematologist-oncologist at the University of California
February 2026
PETAL Consortium highlighted by the American Society of Hematology.
PETAL’s manuscript, “Early Time to Relapse as a Survival Prognosticator in Nodal Mature T-Cell Lymphomas: Results from the PETAL Consortium,” was feat
February 2026
PETAL Consortium highlighted by the American Society of Hematology.
PETAL’s manuscript, “Early Time to Relapse as a Survival Prognosticator in Nodal Mature T-Cell Lymphomas: Results from the PETAL Consortium,” was feat
February 2026
In this Q&A, meet Eric Liu, PETAL Consortium’s Computational Biologist!
Eric Liu, PhD, is a Computational Biologist with PETAL Consortium and a Bioinformatics Scientist at Dana-Farber Cancer Institute. He earned his bachelor’s degree in chemistry and information management and a master’s degree in pharmaceutical sciences from National Taiwan University, followed by a master’s degree in biomedical informatics from Columbia University. He completed his PhD in computational biology at Cornell University and postdoctoral training at Memorial Sloan Kettering Cancer Center.
February 2026
In this Q&A, meet Eric Liu, PETAL Consortium’s Computational Biologist!
Eric Liu, PhD, is a Computational Biologist with PETAL Consortium and a Bioinformatics Scientist at Dana-Farber Cancer Institute. He earned his bachelor’s degree in chemistry and information management and a master’s degree in pharmaceutical sciences from National Taiwan University, followed by a master’s degree in biomedical informatics from Columbia University. He completed his PhD in computational biology at Cornell University and postdoctoral training at Memorial Sloan Kettering Cancer Center.
January 2026
PETAL attends the 17th Annual T-Cell Lymphoma Forum!
This year, PETAL team members met up in San Diego, CA to attend the global gathering of experts dedicated to advancing the understanding and treatment of T-cell lymphomas. This year, PETAL was proud to showcase presentations by Forum Bhanushali, Makoto Iwasaki, Alex Lenart, Kusha Chopra, Kristiana Nasto, Christina Poh, Salvia Jain, and Devavrat Shah.
January 2026
PETAL attends the 17th Annual T-Cell Lymphoma Forum!
This year, PETAL team members met up in San Diego, CA to attend the global gathering of experts dedicated to advancing the understanding and treatment of T-cell lymphomas. This year, PETAL was proud to showcase presentations by Forum Bhanushali, Makoto Iwasaki, Alex Lenart, Kusha Chopra, Kristiana Nasto, Christina Poh, Salvia Jain, and Devavrat Shah.
Explore PETAL
Explore PETAL
Quick access to key PETAL research, programs, and resources.
Quick access to key PETAL research, programs, and resources.
CONTACT US
If you have any questions, please email us at mghpetalstudy@mgb.org!
If you have any questions, please email us at mghpetalstudy@mgb.org!
For Healthcare Professionals
@2026 PETAL Consortium • All rights reserved
For Healthcare Professionals
@2026 PETAL Consortium • All rights reserved